Advertisement

Cannabis as a medicine. An update of the Italian reality

Published:October 31, 2018DOI:https://doi.org/10.1016/j.ejim.2018.10.021
      Cannabis and cannabinoids gained increasing attention for their possible clinical uses, as recently reported in a Special issue of this journal. The Mario Negri Institute recently organized a national conference on the therapeutic potential of clinical use of Cannabis, hosting lectures from main Italian stakeholders in the area. The goal was to clarify the current national regulations regarding production, prescription and availability in Italy, and to evaluate the current state on the clinical use of Cannabis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. D.L. 219/2006. GU n. 142. 21–06- 2006. n.d.

      2. D.M. 23 January 2013. GU n.33. 08-02-2013. n.d.

      3. www.salute.gov.it/imgs/C_17_notizie_1737_listaFile_itemName_0_file.pdf. n.d.

        • Casiraghi A.
        • Roda G.
        • Casagni E.
        • Cristina C.
        • Musazzi U.
        • Franzè S.
        • et al.
        Extraction Method and Analysis of Cannabinoids in Cannabis Olive Oil Preparations.
        Planta Med. 2018; 84: 242-249https://doi.org/10.1055/s-0043-123074
        • MacCallum C.A.
        • Russo E.B.
        Practical considerations in medical cannabis administration and dosing.
        Eur J Intern Med. 2018; https://doi.org/10.1016/j.ejim.2018.01.004
      4. D.M. 9 November 2015. GU n.279. 30-11-2015 and Ministero della Salute. DGMF 12516. 22-02-2017. n.d.

        • Abrams D.I.
        The therapeutic effects of Cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report.
        Eur J Intern Med. 2018; 49: 7-11https://doi.org/10.1016/j.ejim.2018.01.003
        • Committee on the Health Effects of Marijuana
        An Evidence Review and Research Agenda, Board on Population Health and Public Health Practice, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.
        National Academies Press, Washington, D.C.2017https://doi.org/10.17226/24625
        • Finnerup N.B.
        • Attal N.
        • Haroutounian S.
        • McNicol E.
        • Baron R.
        • Dworkin R.H.
        • et al.
        Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.
        Lancet Neurol. 2015; 14: 162-173https://doi.org/10.1016/S1474-4422(14)70251-0
      5. Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, et al. Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 2018:1. doi:https://doi.org/10.1097/j.pain.0000000000001293.

        • Abuhasira R.
        • Shbiro L.
        • Landschaft Y.
        Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North America.
        Eur J Intern Med. 2018; 49: 2-6https://doi.org/10.1016/j.ejim.2018.01.001